Phase II study of Temozolomide monotheraphy in patients with first line treatment-refractory neuroendocrine carcinoma
Not Applicable
Completed
- Conditions
- euroendocrine carcinoma (Grade3)
- Registration Number
- JPRN-UMIN000010549
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
Not provided
Exclusion Criteria
cerebral vascular disease untreatment bone fracture uncontrolable ulcer tendency of bleeding another major carcinoma cerebral vascular disease active infection HBV hepatitis or carrier uncontrolable hypertension intestinal pneumonia past history of intake aboutimmunosuppressive agents tubeluclosis cardiac disease pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall response rate
- Secondary Outcome Measures
Name Time Method overall survival